Legislation and school policies

Schools have a legal duty to make arrangements for pupils with medical conditions (including those with food allergies) under the Children and Families Act 2014. For allergies, this requirement is supported by the statutory guidance Allergy safety in schools. All pupils with medical conditions (including allergies) which have a functional impact on them in their school or educational setting should have an Individual Healthcare Plan agreed between the parents and the school.

This is particularly important where self-administered adrenaline devices (ADs) have been prescribed for use in emergencies.

Teachers and other non-healthcare professionals are permitted – but not obligated – to administer ADs under existing legislation, but only to the person the device has been prescribed. They cannot use an AD prescribed to child ‘A’ to treat anaphylaxis occurring in child ‘B’.

In 2017, the law was changed: the Human Medicines (Amendment) Regulations 2017 now allows schools to obtain, without a prescription, “spare” adrenaline autoinjector (AAI) devices for use in emergencies. Only those institutions described in regulation 22 of the Human Medicines (No.2) Regulations 2014 may legally hold “spare” AAIs – this includes all primary and secondary schools (including independent schools) in the UK.

From September 2026, schools must have an allergy safety policy and must “have regard” to the Allergy safety in schools statutory guidance. Under this guidance, there is an expectation that schools should hold “spare” AAIs, and arrange allergy awareness training for all staff. Under the Children’s Wellbeing and Schools Act 2026, the Government will be bringing in Regulations in 2027 which will make allergy awareness training a legal requirement for schools, and mandate schools to hold spare adrenaline devices for use in an emergency.

Currently, only adrenaline autoinjector (AAI) devices can be obtained as “spare” devices, although this may change in the future.

“Spare” AAI devices can be used in any pupil known to be at risk of anaphylaxis, so long as the school has written approval from both the pupil’s healthcare professional and parent/guardian. Unless medical authorisation and parent/guardian consent have been provided, schools cannot administer the adrenaline device to a pupil having anaphylaxis except in an absolute emergency.

The British Society for Allergy and Clinical Immunology (BSACI) has produced a range of Allergy Action Plans, which can be used for this purpose, as part of the pupil’s individual healthcare plan. Almost all Children’s Allergy clinics in the UK now use the BSACI plans to their patients. The plans can be downloaded here.

Schools don’t have to use the BSACI plans, but then they need to have an alternative in place which includes information on:

  • Known allergens and risk factors for anaphylaxis in the pupil.
  • Whether the pupil has been prescribed an adrenaline device (and if so what type and dose).
  • Whether parental consent has been given for use of the spare adrenaline device.
  • A photograph of the pupil to allow a visual check to be made (this will require parental consent).

Unfortunately, “spare” AAI(s) are not provided free of charge – schools must pay for them. This applies even in those devolved nations where no prescription charge is currently levied.

The Royal Pharmaceutical Society has produced a quick reference guide for Pharmacists receiving requests from schools to supply AAIs.

To help us understand who uses this website please could you tell us whether you are a:

User Type(Required)